Documents

Q1 FY27 delivered 12% sales growth, 11% adjusted profit growth, and a 69.7% gross margin.

Premiumization, rural gains, and digital innovation drive growth ahead of profitability.

Q4 delivered 9% sales growth, robust margins, and accelerated premiumization, with stable outlook.

Q3 FY26 saw 1.4% sales growth and 2.3% profit rise, led by premium segment and margin gains.

Quarterly sales and profit declined, but cash reserves rose and a dividend was announced.

Quarterly revenue and profit declined, with sales down 4.4% year-over-year.

Premiumization and rural growth offset urban softness, driving strong margins and innovation.

Quarterly revenue up 4.7% year-over-year; net profit reached ₹32,278 lakhs.

Double-digit profit growth and a ₹24/share interim dividend highlight strong performance.

Net profit rose 33% year-over-year on 13% sales growth, with EPS reaching ₹13.38.

Oral Health Movement and premium innovation drive growth, with strong financial and ESG focus.